Monnet

Monnet Therapeutics is a Swiss biotechnology company dedicated to developing next-generation cancer immunotherapies that specifically target the tumor microenvironment (TME). Based in the Basel life sciences cluster, the company focuses on engineering therapies that can reprogram the immunosuppressive conditions surrounding solid tumors, thereby enabling a more robust anti-tumor immune response. Their approach is designed to address the limitations of current immunotherapies, particularly for patients who do not respond to standard-of-care checkpoint inhibitors. Monnet's leadership team comprises experienced oncology drug developers who leverage a proprietary platform to advance a pipeline of novel biologics. The company aims to transform 'cold' tumors into 'hot' tumors by modulating the complex cellular and molecular interactions within the tumor niche.